Press Releases
Oct. 4, 2018 Bioasis Announces Investor Relations Service Agreement with Stern IR
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern… Read more »
Aug. 31, 2018 Bioasis Announces Stock Option Grants
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options… Read more »
Aug. 13, 2018 Bioasis Announces Closing of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Jul. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
RICHMOND, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
Jul. 27, 2018 Bioasis Welcomes John E. Curran & David M. Wurzer to the Company’s Board of Directors
Maha Radhakrishnan, M.D. has resigned as a director due to personal reasons
Jul. 25, 2018 Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001 Increased Brain Activity
The Company has filed a patent application based on these observations and those data may have broader applicability
Jul. 16, 2018 Bioasis Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Jul. 11, 2018 Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX , a leading provider of contract bioanalytical testing services with specialization in… Read more »
Jun. 26, 2018 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
RICHMOND, British Columbia & GUILFORD, Conn–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
Jun. 12, 2018 Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early Development and Neurology, Vertex Jack Hoppin, Ph.D., Co-Founder & Chief Executive Officer, Invicro Sue O’Connor, B.Sc. (Hons), Ph.D ., Vice President, Neuroscience Research, Bionomics